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Background:  Autologous bone marrow cells (BMC) transplantation in patients (pts) with critical limb ischemia (CLI) is promising therapeutic 
modality. The question of optimal route of BMC administration is currently unresolved. Accordingly, the aim of our study was to compare the 
therapeutic effects of intramuscular (i.m.) and intraarterial (i.a.) BMC application.
Methods:  In thirty-one pts (age 66±10 years, M:F 27:4) with advance CLI (Rutherford class 5.0±0.2, transcutaneous oxygen pressure /tcpO2/ 
14±9mmHg), after failed or impossible revascularization, we administrated 40ml of isolated bone marrow total nucleated cells (mononuclear cells 
4.4±1.2x10^9, CD34+ 28±19x10^6) into affected limb. After randomization we administrated BMC locally i.m. into the ischemic limb in 16pts, 
and by i.a. infusion (900ml/hour) through the catheter positioned into the popliteal artery in 15pts. In follow-up we evaluated limb salvage, wound 
healing, ΔtcpO2, quality of life (EQ 5D), and pain scoring (0-10). Pts with wound healing and ΔtcpO2>15% were found as responders to BMC 
therapy.
Results:  In 90 days follow-up period the limb salvage was 79% (6 high amputation), two pts die unrelated to BMC procedure. There was significant 
improvement in tcpO2 (14±9 to 35±18mmHg, p<0.001), pain scoring (4.1±2.7 to 0.8±1.3, p<0.001), and EQ 5D (48±14 to 67±13, p<0.01), and 
significant decrease in Rutherford class (5.0±0.2 to 4.5±1.4, p<0.05) in overall group of pts. There was significantly higher CD 34+ cells count, and 
total antioxidant activity of plasma (FRAP), and lower C-reactive protein (CRP) in responders (20pts), compare to non-responders (9pts) to BMC 
therapy (CD34+ 32.3±21x10^6 vs 19±13.4x10^6, p<0.05; FRAP 745±506 vs 485±135 μmol/l, p<0,05; CRP 19±31 vs 72±81 mg/l, p<0.05). 
Importantly, there was no difference in i.m. versus i.a. application in all observed parameters.
Conclusion: The BMC therapy is safe and effective therapeutic strategy for pts with CLI. There is no difference in therapeutic outcomes between i.m. 
and i.a. BMC application. Higher CD34+ cells concentration, higher total antioxidant activity of plasma, and lower degree of inflammation are linked 
to better clinical outcome of the therapy.
